- Combination of NOX66 + internal radiotherapy
- Late-stage prostate cancer patients
- Safety and efficacy study
16 November 2017, Sydney: Noxopharm (ASX:NOX) today announces the treatment of the first patient in the LUPIN study.
The LUPIN Study is an Investigator-Initiated clinical trial being run at St Vincent’s Hospital, Sydney, with Dr Louise Emmett as the Principal Investigator.
For further information please download PDF attached:
Download this document
